Dmytro Shymkiv told how Darnytsia is about to speed up the production of medicines
The Darnytsia pharmaceutical company makes plans to reduce the time for the release of new drugs significantly. This statement was reported by the head of the Board of Directors of Darnytsia, Dmytro Shymkiv. Due to his message, the use of modern IT technologies in the development, testing, and manufacturing of medicines enabled the company to increase its assortment of products and speed up the production rates.
The company’s objectives are pretty high. As the Darnytsia Group management reported, by the end of 2021, the factory intends to manufacture over 25 pharmaceutical brands. Moreover, the total number of items will be more than fifty presented, and every fourth output from this list will be delivered to pharmacy chains four months earlier than the scheduled timetable. The systematic implementation of innovative methods and technologies facilitated such a breakthrough in increasing production turnovers into the company's work. Dmytro Shymkiv mentioned this repeatedly in his interviews and public speeches.
By carrying out on-time, regular and large investments of about UAH 100 million and the early start of digital transformations of production processes, it positively affected the speed in registration and changes in the drug records. Due to this, the company could also reach the risk minimization caused by quarantine restrictions. According to Shymkiv, a comprehensive modernization within the company opened access to new opportunities. It allowed Darnytsia to register a new product every two weeks during 2020. Also, it enabled the factory to provide the process of re-registration of its products weekly.
When it comes to the importance and necessity of digital transformations, Dmytro Shymkiv noted that recently there had been a strong tendency in the healthcare system concerned with the IT industry’s enhancement. The symbiosis of high technologies and medicine will move on developing and strengthening forward. This will allow to minimize the timing of development, research, and production of pharmaceutical products as well as to significantly increase the level of medicine in all directions: from prevention and diagnosis to therapy. In addition, the employees of Darnytsia are closely engaged in the ongoing study of genetic data. Such studies enable to improve the predictive rate of human disease. Furthermore, the pharmaceutical concern transferred entirely to the electronic monitoring of drug use and began using digital master files (eTMF) in the process of clinical trials.
22.05.2021
